Table 2. Relationships between intratumoral/peritumoral CD163 expression and clinicopathologic features.

Variables	Intratumoral CD163 expression		Peritumoral CD163 expression
	Average level or correlationcoefficient*	P	Average level or correlationcoefficient*	P
Age, y	0.184	0.001	0.001	0.984
Gender, male vs female	0.025±0.036 vs. 0.017±0.024	0.155	0.037±0.040 vs. 0.033±0.040	0.499
Hepatitis B history, yes vs. no	0.023±0.032 vs. 0.025±0.040	0.665	0.037±0.043 vs. 0.037±0.027	0.963
Hepatitis B e antigen, positive vs.negative	0.023±0.035 vs. 0.023±0.034	0.933	0.040±0.036 vs.0.035±0.042	0.325
ALT	−0.019	0.744	0.051	0.387
AST	0.047	0.429	0.136	0.021
γ-GT	0.048	0.409	0.139	0.017
ALP	0.125	0.033	0.103	0.079
Liver cirrhosis, yes vs. no	0.023±0.037 vs. 0.023±0.023	0.930	0.039±0.042 vs. 0.030±0.031	0.087
α-Fetoprotein	0.001	0.987	0.159	0.006
Tumor size	0.048	0.410	0.276	<0.001
Tumor encapsulation, complete vs. no	0.024±0.033 vs. 0.022±0.035	0.692	0.033±0.032 vs. 0.040±0.046	0.165
Microvascular invasion, yes vs. no	0.022±0.028 vs. 0.024±0.037	0.615	0.043±0.047 vs. 0.033±0.034	0.037
Tumor differentiation, I–II vs. III–IV	0.023±0.034 vs. 0.023±0.033	0.973	0.036±0.039 vs. 0.038±0.042	0.642
TNM stage, I vs. II/IIIA	0.024±0.039 vs. 0.022±0.027	0.516	0.033±0.035 vs. 0.041±0.044	0.085

^*If the clinicopathologic variable is a quantitative one, Spearman correlation analysis was performed and the correlation coefficient was presented.

Abbreviations: y, year; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, γ-glutamyl transpeptidase; ALP, alkaline phosphatase.